VALARTH See Krishna Institute of Medical Sciences in the appOpen in app
KIMS · NSE · Hospital

Krishna Institute of Medical Sciences Ltd

What the numbers mean, from its filings and the exchange. Data as of 13 Oct 2026.
Small Cap · AMFI list Jan-Jun 2026 · Vendor sector: Healthcare
No valuation view.No view: a loss-maker (growth stage), so earnings multiples do not apply.
Statements through FY2026Prices adjusted for corporate actionsNot yet reviewed by the adversarial model

What is Krishna Institute of Medical Sciences's share price today?

Krishna Institute of Medical Sciences last traded at ₹692.85 on the NSE, as of 13 Oct 2026, 11:45 am IST, down 1.6% on the day, down 1.3% over a year. Its 52-week range is ₹576 to ₹858. The live price is in the app.

₹692.85 −1.6% today
−1.3% over 1 year · NSE, as of 13 Oct 2026, 11:45 am IST
60 month-end closes, 31 Oct 2021 to 30 Sep 2026, adjusted for splits and bonuses
52-week range41% of the way up
Low ₹576High ₹858

What is Krishna Institute of Medical Sciences's market cap?

Krishna Institute of Medical Sciences's market capitalisation is about ₹29,577 crore: what it would cost to buy every share at today's price. That makes it the 47th largest small cap company we cover.

₹29,577 Cr Small Cap47th largest small cap company
Small Cap means the companies ranked 251 and below by size, under SEBI's rules. Shares in issue are worked out from the market cap and the price. What market cap tells you →

Key facts

From the exchange
Symbol
NSE: KIMS
ISIN
INE967H01025
Cap bucket
Small Cap, 47th largest by market cap
Industry (NSE)
Healthcare › Healthcare Services › Hospital
Listed since
2021
Futures and options
Not traded

Is Krishna Institute of Medical Sciences overvalued?

No valuation view yet. No view: a loss-maker (growth stage), so earnings multiples do not apply.

Valuation

Latest price and trailing 12 months
P/E 138.33
Industry 92.23
Price divided by last year's earnings per share: how many years of today's profit you pay for. Learn more →
P/B 10.25
Price divided by book value per share: what you pay for each rupee of net assets on the balance sheet. Learn more →
Market cap ₹29,577 Cr
Total market value of all shares, in ₹ crore. Learn more →
Dividend yield Not available
Last year's dividends as a share of today's price. Learn more →
PEG (vendor) Not available
P/E divided by the vendor's earnings growth figure, which it does not disclose; a P/E adjusted for how fast profits grow. Learn more →
PEG on our 3-year EPS growth Not available
P/E divided by the 3-year EPS growth rate from the stored accounts. Learn more →
3 models could be judged
Skipped — Fair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored

Our valuation range

🔒 Pro
Value range, implied growth at today's price, and the nine models behind it: in the app.

Is Krishna Institute of Medical Sciences a quality business?

Quality score 27; CAUTION on 28 of 30 flags judged.

Quality and risk

Data as of 13 Oct 2026
Business quality Not available
The kind of business, which sets the yardstick it is judged by. Learn more →
Quality score 27
among 14 companies
Returns, margins, leverage and consistency against its peers, out of 100. Learn more →
Risk level CAUTION
28 of 30 flags judged
From flags on debt, earnings quality, dilution and price swings. Learn more →

Profitability

ROE 11.3%
Return on equity: profit as a share of shareholders' money. Learn more →
ROCE 12.6%
Return on capital employed: operating profit as a share of all the capital in the business, debt and equity. Learn more →
Profit margin 4.8%
vs peers 10.9% · 13th of 14
Profit after everything, as a share of revenue. Learn more →
EPS ₹6.05
Trailing 12 months
Profit for each share over the last 12 months.

Scorecard

🔒 Pro
Health scores and red flags with their values and history: in the app.
See the scorecard →
Inside the app

Get a sneak peek of Valarth

Start freeStart free
A Valarth stock page: the share price with its chart and 52-week range, valuation and profitability figures, and a scorecard of health checks.
Stock pagePrice, valuation, profitability and a scorecard of health checks for every company, each figure explained.
The Valarth stock screener: a table of companies with price, market cap, P/E, P/B, PEG, EPS and ROE, and filters down the left.
ScreenerEvery listed company, filtered on 212 figures, each with a plain-language lesson beside it.
The Valarth AI Screener answering 'Which companies will benefit from India's Project 75 submarine programme?' with a basket of four naval shipbuilders and a written thesis.
AI ScreenerAsk a question in plain English, like which companies benefit from India's Project 75. It reads the intent, builds the screen and writes the thesis.
A Valarth business-model card for State Bank of India, with a plain-language summary and statements verified against the filing.
Business modelHow a company makes money and what can hurt it, each statement checked against its annual report.
Valarth's Before the Bell edition, with the day's headline, regulator notes and sector moves.
Before the BellA morning edition before the market opens: what moved, which rule changed, and what it means for your holdings.

Has Krishna Institute of Medical Sciences made money for shareholders?

Mixed: −1.3% over one year and +25.0% a year over five years.

Shareholder returns

1-year return −1.3%
Price only
What the share price did over the last 12 months. Learn more →
5-year return +25.0% a year
Price only
Yearly average price return over five years, bonuses and splits adjusted. Learn more →
Wealth destroyer No
Five-year total return — price CAGR on bonus- and split-adjusted closes plus the dividend yield — below the 7% a bank fixed deposit paid. Learn more →

Returns

3Y and 5Y are yearly averages
1W
+1.6%
1M
−8.2%
3M
−12.1%
6M
+7.1%
1Y
−1.3%
3Y
+25.5%
5Y
+25.0%

Is Krishna Institute of Medical Sciences growing?

Revenue 3 years 20.7% a year; profit 3 years -10.5% a year; revenue 5 years 20.4% a year.

Growth

Statements through FY2026 (Mar-26)
Revenue 3 years 20.7% a year
vs peers 18.0% · 4th of 14
Compound annual growth of revenue over three years. Learn more →
Profit 3 years -10.5% a year
Compound annual growth of net profit over three years. Learn more →
Revenue 5 years 20.4% a year
Compound annual growth of revenue over five years. Learn more →
Profit 5 years -9.3% a year
Compound annual growth of net profit over five years. Learn more →
EPS 3 years -10.5% a year
Growth in earnings per share, so dilution counts against the company. Learn more →
EPS 5 years 41.6% a year
Growth in earnings per share over five years, so dilution counts against the company. Learn more →
P/E vs own history 55.2%
Today's P/E against its own 5-year median; negative is cheaper than its history. Learn more →

How did Krishna Institute of Medical Sciences do last quarter?

Krishna Institute of Medical Sciences reported revenue of ₹1,180 Cr, up 28.6% on a year earlier and a net profit of ₹37 Cr, down 41.7% in the Jun 2026 quarter.

Latest quarter

Jun 2026
Revenue, latest quarter₹1,180 Cr
+28.6% on a year earlier
What the company took in over the quarter.
Net profit, latest quarter₹37 Cr
−41.7% on a year earlier
What was left for shareholders after every cost and tax.

How does Krishna Institute of Medical Sciences compare with its peers?

Compared with 13 Hospital; the ranks are in the app.

Compared with 13 Hospital

13 companies

Krishna Institute of Medical Sciences against its peers

Largest 10 of 13 peers, by market cap
CompanyMarket capP/EP/BROEROCE1YQuality 🔒Rank 🔒
Krishna Institute of Medical Sciences Ltd₹29,577 Cr138.310.211.3%12.6%−1.3%
Apollo Hospitals Enterprise Ltd₹1.1 L Cr55.210.716.0%17.5%+1.4%
Manipal Health Enterprises Ltd₹89,321 Cr93.8—6.9%8.4%+1.8%
Max Healthcare Institute Ltd₹84,284 Cr59.010.58.3%10.3%−24.3%
Aster DM Quality Care Ltd₹59,221 Cr113.28.89.6%10.9%−3.0%
Fortis Healthcare Ltd₹57,169 Cr56.66.52.1%4.0%−30.9%
Global Health Ltd₹35,206 Cr63.46.413.2%15.9%−3.9%
Narayana Hrudayalaya Ltd₹34,582 Cr42.812.621.0%18.4%−3.8%
Dr Agarwals Health Care Ltd₹15,065 Cr101.96.51.9%5.0%−8.5%
Rainbow Childrens Medicare Ltd₹12,483 Cr44.57.015.7%17.3%−7.7%
Park Medi World Ltd₹10,995 Cr37.59.57.5%10.0%+72.0%
Peer median—————−3.7%
Market cap in rupees crore; P/E and P/B on the latest price; 1Y is the price return over a year. A dash is a figure that does not apply or is not reported.

Full peer comparison

🔒 Pro
Every peer, every figure, the ranks and the quality and forensic scores side by side: in the app.

Who owns Krishna Institute of Medical Sciences?

Krishna Institute of Medical Sciences is held by promoters 32.5%, foreign institutions 14.7%, domestic institutions 34.4%.

Shareholding pattern

Latest filing, percent of shares
Promoters32.5%
The founders and controlling group.
Foreign institutions14.7%
Overseas funds investing through the FPI route.
Domestic institutions34.4%
Indian insurers, banks, pension and mutual funds together.
Mutual funds28.5%
Indian mutual fund schemes; part of domestic institutions.
Retail and others3.9%
Individual investors and everyone else.
Promoter shares pledged🔒 In the app
Promoter shares given as collateral for loans; a high share is a risk to watch.
Holding trend🔒 In the app
Whether promoters, foreign funds and mutual funds have been adding or selling over recent quarters.

What do analysts say about Krishna Institute of Medical Sciences?

14 analysts cover Krishna Institute of Medical Sciences, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Analyst consensus

14 analysts
ConsensusBuy
The rating most covering analysts give the share.
Average target price🔒 In the app
The mean of the analysts' 12-month price targets.
Upside to target🔒 In the app
How far the target sits above or below today's price.
Share rating it a buy🔒 In the app
The share of covering analysts with a buy rating.

What does Krishna Institute of Medical Sciences do and what is it sensitive to?

Krishna Institute of Medical Sciences Limited (KIMS) runs hospitals in India and earns from inpatient and outpatient hospital fees, pharmacy sales and Operating & Maintenance contract fees. Sensitive to: interest rates on variable-rate borrowings.

Business-model card

FY2025 · 38 verified
4Revenue
3Channels
3Regulators
4Reg. dependencies
6Sensitivities
4Costs
3Geographies

Krishna Institute of Medical Sciences Limited (KIMS) runs hospitals in India and earns from inpatient and outpatient hospital fees, pharmacy sales and Operating & Maintenance contract fees. Its customers are self-paying patients and beneficiaries of government-sponsored health schemes, both insured and uninsured.

Revenue engine

4 verified
Hospital services (inpatient and outpatient fees)
Fees charged for inpatient and outpatient hospital services, including accommodation, surgery, clinical professional services, food and beverages, investigations and supply of pharmaceutical products.
Pharmacy sales
Revenue from sale of pharmacy items, recognised when control of goods passes to the customer at a point in time.
Operating & Maintenance (O&M) contract medical service fee
Revenue from O&M contracts is recognised over time as services are received and accepted by the customer. Interpretation: the excerpts do not state the contract counterparties or the size of this line.
1 more statement
Single reportable segment
The filing treats medical and healthcare services as one business segment for resource allocation and performance assessment.

Customers & channels

3 verified
Self-paying patients
Patients who pay for services directly, one of two customer groups the filing names.
Government health scheme beneficiaries
Beneficiaries of government-sponsored schemes such as CGHS and ECHS. Interpretation: these schemes are payers for part of the revenue, so changes in scheme coverage or rates would affect this group's volume and pricing.
Insured and uninsured domestic patients
The filing says the domestic clientele includes both insured and uninsured individuals across regions in India.

Regulators

3 verified
State Pollution Control Board
Sets norms that the company's waste management policy must comply with, together with the Biomedical Waste Management Rules.
Clinical Establishments (Registration and Regulation) Act, 2010
Listed as a law specifically applicable to the company, which operates hospitals. Interpretation: this law governs establishment registration and regulation for the hospital business.
The Indian Medical Council Act, 1956
Listed as a law specifically applicable to the company. Interpretation: it governs the medical profession whose services the company sells.

Regulatory dependencies

4 verified
Biomedical waste rules
Improper handling can lead to regulatory violations and environmental harm. Interpretation: a tighter rule would raise waste handling cost, and a violation would carry penalty cost.
Compliance with laws applicable to the company
Non-compliance can lead to legal action and reputational damage. Interpretation: changes in these laws would raise compliance cost or constrain how services are delivered.
Patient data protection under evolving laws
Handling sensitive patient data creates exposure to privacy risks under evolving laws. Interpretation: stricter privacy rules would raise IT and compliance cost.
1 more statement
Data breach and regulatory penalties
Breaches could compromise patient confidentiality and lead to regulatory penalties. Interpretation: penalties would be a direct cost to earnings.

Sensitivities

6 verified
Interest rates on variable-rate borrowings
A 1% increase in MCLR reduces profit by 71 (million rupees, per the standalone table at 31 March 2025). Interpretation: a rise in rates lowers profit, and a fall raises it by the same amount.
Variable-rate borrowings base
Variable-rate long and short term borrowings were 7,080 at 31 March 2025 (3,263 at 31 March 2024), so the interest rate sensitivity grows with debt.
Loan covenant breach
Secured bank loans carry covenants, and a future breach may require earlier repayment. Interpretation: a covenant breach would raise short-term cash needs.
3 more statements
US dollar exposure
The filing states its currency exposure relates to foreign currency payables and receivables, denominated in USD. The filing states it has no unhedged foreign currency exposure at 31 March 2025.
Input cost inflation
The filing lists inflation and input cost escalation as a risk, mitigated through procurement and supplier agreements. Interpretation: higher input inflation would raise costs unless offset.
Natural disasters and policy volatility in core regions
Concentration in two states exposes capacity and revenue to natural disasters, political shifts or policy volatility.

Cost inputs

4 verified
Specialist physician remuneration
Specialist physicians are paid per service rendered. Interpretation: wage pressure from talent shortages would raise this cost.
Skilled staff compensation
Shortage of skilled professionals or shifts in market demand may require higher pay to attract and retain talent.
Medical supplies procurement
Supplier delays or disruptions in medical supplies can interrupt service continuity.
1 more statement
Consultancy charges (consolidated expense line)
Consolidated table shows 6,838 for FY2025 and 5,494 for FY2024. Interpretation: the excerpt does not say who receives these fees.

Geographies

3 verified
Predominantly India
Operations are predominantly confined in India, and all non-current assets other than financial instruments and deferred tax assets are located in India.
Andhra Pradesh and Telangana
A significant portion of capacity and revenue is concentrated in these two states.
National presence in two states
Locations are reported as national, with 2 states and 0 countries.
Each statement is checked word for word against the FY2025 annual report; the passages are in the app.

What changed recently?

Q1 FY2027 results filed (3 Aug 2026).

Change log

6 entries · newest first
  1. Results filedQ1 FY2027 results filed.
  2. Results filedQ4 FY2026 results filed.
  3. Results filedQ3 FY2026 results filed.
  4. Results filedQ2 FY2026 results filed.
  5. Results filedQ1 FY2026 results filed.
  6. Results filedQ4 FY2025 results filed.
Get alerts →Sign in to be told when any of these change.

What this page does not tell you

What could not be judged, and why. Never empty.
  • Models not runFair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored.
  • FlagsCAUTION on 28 of 30 flags judged; 3 red; 2 could not be judged.
  • Data gapsDividend yield, PEG (vendor), PEG on our 3-year EPS growth, Business quality: not available yet.
Not applicable to this company · 1
  • Altman ZAltman Z is a manufacturing model; a service business has no inventory or plant turnover for it to read.

What this page rests on

✓10 years of annual statements, through FY2026 (Mar-26)✓10 quarters of results✓64 months of month-end prices, adjusted for bonuses and splits○no valuation of ours yet✓business-model card FY2025 · 38 verified

Questions people ask

What is Krishna Institute of Medical Sciences's share price today?

Krishna Institute of Medical Sciences last traded at ₹692.85 on the NSE, as of 13 Oct 2026, 11:45 am IST, down 1.6% on the day, down 1.3% over a year. Its 52-week range is ₹576 to ₹858. The live price is in the app.

What is Krishna Institute of Medical Sciences's market cap?

Krishna Institute of Medical Sciences's market capitalisation is about ₹29,577 crore: what it would cost to buy every share at today's price. That makes it the 47th largest small cap company we cover.

Is Krishna Institute of Medical Sciences Ltd a large cap, mid cap or small cap?

Krishna Institute of Medical Sciences Ltd (KIMS) is a small cap company in AMFI's classification for Jan-Jun 2026. SEBI's buckets go by rank on six-month average market capitalisation: the top 100 are large caps, 101 to 250 mid caps, the rest small caps.

What is Krishna Institute of Medical Sciences Ltd's P/E ratio?

138.33, Industry 92.23. Price divided by last year's earnings per share: how many years of today's profit you pay for.

How does Krishna Institute of Medical Sciences Ltd make money?

Krishna Institute of Medical Sciences Limited (KIMS) runs hospitals in India and earns from inpatient and outpatient hospital fees, pharmacy sales and Operating & Maintenance contract fees. Its customers are self-paying patients and beneficiaries of government-sponsored health schemes, both insured and uninsured.

Who are Krishna Institute of Medical Sciences Ltd's peers?

Compared with 13 Hospital: Apollo Hospitals Enterprise Ltd, Manipal Health Enterprises Ltd, Max Healthcare Institute Ltd, Aster DM Quality Care Ltd, Fortis Healthcare Ltd and 8 more. The app shows how they compare on every figure.

Is this investment advice?

No. Valarth is a research and learning tool and is not a SEBI-registered investment adviser or research analyst. The figures come from the company's filings and the exchanges; what to do with them is your call.

How did Krishna Institute of Medical Sciences do last quarter?

Krishna Institute of Medical Sciences reported revenue of ₹1,180 Cr, up 28.6% on a year earlier and a net profit of ₹37 Cr, down 41.7% in the Jun 2026 quarter.

Who owns Krishna Institute of Medical Sciences?

Krishna Institute of Medical Sciences is held by promoters 32.5%, foreign institutions 14.7%, domestic institutions 34.4%.

What do analysts say about Krishna Institute of Medical Sciences?

14 analysts cover Krishna Institute of Medical Sciences, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

More small cap companies

Manappuram Finance LtdMANAPPURAM · ₹30,059 CrNetweb Technologies India LtdNETWEB · ₹29,730 CrACME Solar Holdings LtdACMESOLAR · ₹29,600 CrInventurus Knowledge Solutions LtdIKS · ₹29,596 CrTata Technologies LtdTATATECH · ₹29,083 CrHoneywell Automation India LtdHONAUT · ₹28,664 CrAditya Birla Sun Life AMC LtdABSLAMC · ₹28,558 CrSchneider Electric Infrastructure LtdSCHNEIDER · ₹28,348 Cr
All companies, by market cap →

Everything on Krishna Institute of Medical Sciences, and 6,621 other companies, with 212 filters and the full peer tables

See Krishna Institute of Medical Sciences in the app →See pricing